In a subchronic toxicity study (MRID  if available) [Chemical name, (%a.i.)] was administered to [(# of animals) species, strain]/sex/dose in [diet, water, by capsule, by gavage] at dose levels of 0, x, x, x ppm (0, x, x, x  mg/kg bw/day).

 

[Describe toxicity briefly following instructions for exec summary paragraph 2.  If there is no toxicity, state that there were no compound related effects in mortality, clinical signs, body weight, food consumption, hematology, clinical chemistry, organ weights, or gross and histologic pathology.  Note if there was a NOAEL for clinical findings (for Acute reference dose consideration during subsequent risk assessment.)]The LOAEL is      , based on           .  The NOAEL is    .

 

This subchronic toxicity study in the dog is [acceptable, unacceptable(why); note if it is a range-finding study] and satisfies (does not satisfy) the guideline requirement for a subchronic oral study (OPPTS 870.3150; OECD 409) in dogs.  [If it does not satisfy the requirement, concisely list only major deficiencies or refer to deficiency section.]